<DOC>
	<DOCNO>NCT01330589</DOCNO>
	<brief_summary>The purpose study evaluate whether patient post PCI receive clopidogrel carrier least one CYP 2C19 loss-of-function allele may achieve improve pharmacodynamic efficacy clopidogrel treat CYP 2C19 enzyme inducing agent , St. John 's wort , compare placebo . Hypothesis 1 . Reduced platelet reactivity present patient receive St. John 's wort compare placebo utilized combination clopidogrel 2 . The combination St. John 's wort clopidogrel result enhance platelet inhibition</brief_summary>
	<brief_title>Pharmacodynamic Study Efficacy Clopidogrel With St. John 's Wort</brief_title>
	<detailed_description>Objective The purpose study evaluate whether patient post PCI receive clopidogrel carrier least one CYP 2C19 loss-of-function allele may achieve improve pharmacodynamic efficacy clopidogrel treat CYP 2C19 enzyme inducing agent , St. John 's wort , compare placebo . Specific Aims 1 . To identify difference platelet reactivity patient receive St. John 's wort placebo 2 . To characterize difference platelet inhibition patient receive St. John 's wort placebo Hypothesis 1 . Reduced platelet reactivity present patient receive St. John 's wort compare placebo utilized combination clopidogrel 2 . The combination St. John 's wort clopidogrel result enhance platelet inhibition Study Design The study prospective , randomize , double-blind , placebo-controlled , cross-over study patient post PCI require dual-antiplatelet therapy aspirin clopidogrel . Approximately 84 patient enrol undergo pharmacogenetic test assess clopidogrel responsiveness utilize CYP P450 2C19 genotyping ( PlavitestÂ® ) . Based upon assumption 30 % genetic non-responsiveness dropout rate 20 % , achieve final sample size 20 subject randomize crossover portion study , investigator need enroll approximately 84 subject . Patients identified carrier least one CYP 2C19 loss-of-function allele ( i.e . clopidogrel reduced-metabolizers ) remain study randomly assign receive placebo St. John 's wort . Patients carry CYP 2C19 loss-of-function allele ( i.e . clopidogrel normal metabolizers ) require follow-up patient consider display normal response clopidogrel . On day 7 follow initiation study drug , platelet function test perform . Following 7 day washout period , patient cross study group receive 7 day study medication . On day 21 , patient undergo platelet function test study medication discontinue .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Patients age 18 old Patients history ACS and/or receive PCI stent placement Lancaster General Hospital require dual antiplatelet therapy aspirin clopidogrel . Patients active known history bleed gastrointestinal , intracranial , bleeding diathesis History major surgery last year ( surgical procedure involve general anesthesia respiratory assistance ) Clinical finding associate increase risk bleed judgment investigator Patients actively receive anticoagulation therapy Hemoglobin &lt; 10 g/dL Platelets &lt; 150,000/mm3 Known hepatic dysfunction History intracranial malignancy stroke Patients receive thienopyridines chronically prior PCI Concurrent use CYP P450 2C19 substrate , inhibiting/ induce medication exception proton pump inhibitor Illicit drug alcohol abuse Daily treatment nonsteroidal antiinflammatory drug cyclooxygenase2 inhibitor Allergy St. Johns wort lactose Patients expect discontinue dual antiplatelet therapy prior completion study protocol Patients unable adhere study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>St. John 's Wort</keyword>
	<keyword>CYP 2C19 loss-of-function allele</keyword>
</DOC>